Keith Michael Gottesdiener - Net Worth and Insider Trading
Keith Michael Gottesdiener Net Worth
The estimated net worth of Keith Michael Gottesdiener is at least $9 Million dollars as of 2023-06-09. Keith Michael Gottesdiener is the CEO & President of Rhythm Pharmaceuticals Inc and owns about 506,342 shares of Rhythm Pharmaceuticals Inc (RYTM) stock worth over $9 Million. Keith Michael Gottesdiener is also the Director of Intercept Pharmaceuticals Inc and owns about 5,001 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $61,262. Details can be seen in Keith Michael Gottesdiener's Latest Holdings Summary section.
Transaction Summary of Keith Michael Gottesdiener
Keith Michael Gottesdiener Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Keith Michael Gottesdiener owns 3 companies in total, including Intercept Pharmaceuticals Inc (ICPT) , Rhythm Pharmaceuticals Inc (RYTM) , and Prime Medicine Inc (PRME) .
Click here to see the complete history of Keith Michael Gottesdiener’s form 4 insider trades.
Insider Ownership Summary of Keith Michael Gottesdiener
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ICPT | Intercept Pharmaceuticals Inc | 2020-05-28 | director |
| RYTM | Rhythm Pharmaceuticals Inc | 2017-10-04 | director & CEO and President |
| PRME | Prime Medicine Inc | 2022-10-19 | director & See Remarks |
Keith Michael Gottesdiener Latest Holdings Summary
Keith Michael Gottesdiener currently owns a total of 2 stocks. Among these stocks, Keith Michael Gottesdiener owns 506,342 shares of Rhythm Pharmaceuticals Inc (RYTM) as of March 18, 2019, with a value of $9 Million and a weighting of 99.31999999999999%. Keith Michael Gottesdiener also owns 5,001 shares of Intercept Pharmaceuticals Inc (ICPT) as of April 9, 2018, with a value of $61,262 and a weighting of 0.68%.
Latest Holdings of Keith Michael Gottesdiener
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals Inc | 2019-03-18 | 506,342 | 17.60 | 8,911,619 |
| ICPT | Intercept Pharmaceuticals Inc | 2018-04-09 | 5,001 | 12.25 | 61,262 |
Holding Weightings of Keith Michael Gottesdiener
Keith Michael Gottesdiener Form 4 Trading Tracker
According to the SEC Form 4 filings, Keith Michael Gottesdiener has made a total of 9 transactions in Rhythm Pharmaceuticals Inc (RYTM) over the past 5 years, including 0 buys and 9 sells. The most-recent trade in Rhythm Pharmaceuticals Inc is the sale of 10,290 shares on March 18, 2019, which brought Keith Michael Gottesdiener around $309,626.
According to the SEC Form 4 filings, Keith Michael Gottesdiener has made a total of 0 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years. The most-recent trade in Intercept Pharmaceuticals Inc is the acquisition of 1,171 shares on April 9, 2018, which cost Keith Michael Gottesdiener around $74,944.
Insider Trading History of Keith Michael Gottesdiener
- 1
Keith Michael Gottesdiener Trading Performance
GuruFocus tracks the stock performance after each of Keith Michael Gottesdiener's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Keith Michael Gottesdiener is 36.02%. GuruFocus also compares Keith Michael Gottesdiener's trading performance to market benchmark return within the same time period. The performance of stocks bought by Keith Michael Gottesdiener within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Keith Michael Gottesdiener's insider trading performs compared to the benchmark.
Performance of Keith Michael Gottesdiener
Average Relative Return
70.98%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | 3.99 | 36.02 | 54.45 | 70.98 | 0.01 | -31.56 |
| Relative Return to S&P 500(%) | 0.75 | 29.48 | 44.23 | 60.84 | -3.31 | -48.02 |
Keith Michael Gottesdiener Ownership Network
Ownership Network List of Keith Michael Gottesdiener
Ownership Network Relation of Keith Michael Gottesdiener
Keith Michael Gottesdiener Owned Company Details
What does Intercept Pharmaceuticals Inc do?
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Who are the key executives at Intercept Pharmaceuticals Inc?
Keith Michael Gottesdiener is the director of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .
Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Intercept Pharmaceuticals Inc Insider Transactions
Keith Michael Gottesdiener Mailing Address
Above is the net worth, insider trading, and ownership report for Keith Michael Gottesdiener. You might contact Keith Michael Gottesdiener via mailing address: 900 Fifth Avenue, #8c, New York Ny 10021.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
